FindTrial
Sign In

Protective effect of matrix metalloproteinase inhibitor in extracorporeal circulation

Protective effect of matrix metalloproteinase inhibitor in extracorporeal circulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011339
Enrollment
Unknown
Registered
2017-05-09
Start date
2017-05-11
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart disease

Interventions

Experience group:Oral doxycycline

Sponsors

Department of Anesthesiology of The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. heart surgery; 2. aged from 18 to 85 years.

Exclusion criteria

Exclusion criteria: 1. diabetes mellitus; 2. Renal insufficiency.

Design outcomes

Primary

MeasureTime frame
Matrix metalloproteinase, glycocalyx;—

Countries

China

Contacts

Public ContactWei Gao

The First Affiliated Hospital of Wenzhou Medical University

13736360269@163.com+86 13736360269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026